FROM ARRAY Array’s Drug Binimetinib in Combination Therapy with Merck’s Drug Keytruda for METASTATIC FOR COLORECTAL CANCER   On May 8, 2017, Array BioPharma and Merck announced entering into a clinical trial collaboration to investigate the safety and efficacy of Array's MEK inhibitor, binimetinib, with Merck's anti-PD-1 therapy, Keytruda® (pembrolizumab), in metastatic colorectal cancer patients with microsatellite stable tumors (MSS CRC). The decision on this …

As we wrote yesterday, immunotherapy checkpoint inhibitors represent a great advancement and big changes in the management of cancer. It is pertinent, though, to keep in mind that these immuno-oncology products will not be successful with all cancers. Immune checkpoint inhibitors Keytruda (Merck) and Obdivo, Bristol-Myers Squibb and others are already approved around the world for several cancers. We also know that these immunotherapy products …

Additional Combination Treatment with Vectibix  for Metastatic Colorectal Cancer (mCRC) The Old Drug: VECTIBIX                   The Company: AMGEN Colon cancer is easy to cure when discovered early. Missing the diagnosis of early colon cancer could result in cancer growth, direct spread, distal metastasis and death. In spite of the tremendous improvement of treatments, advanced colon cancer is still …

On June 22, 2017, the U.S. Food and Drug Administration (FDA) has approved Genentech’s Rituxan Hycela™. This product is a combination of Genentech’s drug rituximab and Halozyme's hyaluronidase enzyme through Halozymes’s proprietary human ENHANZE® technology. The aim of the combination is changing Rituxan from an intravenously administered product into a subcutaneous (under the skin) injection. The new version Rituxan Hycela is expected to reduce the …

IMPRESSIVE RESULTS?  Bellicum Pharmaceuticals’ (BLCM) drug BPX-501 is described as a safe and effective product that can offer children with cancer and other serious diseases the opportunity to beat their intractable sicknesses. The drug enables the patients who are in desperate need for a bone marrow stem cell transplant to use unmatched donors’ stem cells through lowering their adverse effects. The most recent clinical trial …

Portola (PTLA) announced that the U.S. Food and Drug Administration (FDA) has approved Bevyxxa (betrixaban), the first anticoagulant for hospital and extended duration prophylaxis (35 to 42 days) of venous thromboembolism (VTE) in adult patients hospitalized for an acute medical illness who are at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE. Bevyxxa’s approval is on …

As we wrote in Prohost Letter #409, a transformation in this year’s American Society of Clinical Oncology meeting (ASCO) is further elaborating on Checkpoint inhibition and chimeric antigen receptor T-cell (CAR-T) approaches’ limitations. Both are attempts towards making Immunotherapy for cancer a successful treatment. Checkpoint inhibitors have reached the market at the hands of Merck, Bristo-Myers Squibb and Roche, with other firms coming forward with products …

Alnylam Pharmaceutical (ALNY) calls RNAi (RNA interference) a revolution in biology. The FDA’s just granted the firm’s RNAi therapy breakthrough for a disease nobody has ever dreamed of conquering confirms this reality in spite of spending years of efforts and money towards turning the RNAi molecules into therapeutic molecules that can be used safely and effectively. RNAi-related treatments represent a completely new approach to drug …

It is obvious that the CAR-T approach to cancer treatment is here to stay and to change the way cancer has been managed for decades. Attempts to improve the novel elegant procedure safety profile and efficacy on solid cancers are being pursued by academia as well as by biotechnology and pharmaceutical companies. Kite Pharma’s (KITE) CAR-T therapy axicabtagene ciloleucel is an investigational therapy in which …

Amgen’s (AMGN) and UCB's drug Evenity (romosozumab), which, in long and large 24 months of clinical investigation has demonstrated superior results in reducing new vertebral, non vertebral and clinical bone fractures, has demonstrated a heart-related side effects. At the weekend Amgen announced results from Phase 3 trials demonstrating that its product Evenity (romosozumab) met the primary and secondary endpoints of the trials, which relate to  reducing the …

PTC THERAPEUTICS Why Buying Emflaza? Buying Emflaza, a steroid approved by the FDA for Duchenne muscular dystrophy (DMD) from Marathon Pharmaceuticals invited an intractable headache to PTC Pharmaceuticals’ shareholders and scrutiny by some law makers. The cause of the law makers’ involvement has been the Marathon’s pricing Emflaza at $89,000, but PTCT shareholders had several question marks revolving around the motive for buying this drug …

GENE EDITING Sangamo Biosciences: Is it a Comeback? Genome editing allows the creation of therapeutics that can modify the genome in a living cell, providing unprecedented reach that would help the creation of treatments for genetic diseases. The dream about emerging solutions through genome editing techniques, which could correct genetic mutations causing diseases seems to be turning into reality. Among the innovative firms in this …

Positive results were announced from Array’s (ARRY) Part 2 of the Phase 3 COLUMBUS study evaluating the firm’s MEK inhibitor drug binimetinib, and its BRAF inhibitor drug encorafenibin in patients with BRAF-mutant advanced, unresectable or metastatic melanoma. The part 2 of the Phase 3, which intended to compare progression free survival (PFS) in patients treated with binimetinib plus encorafenib (COMBO300) to patients treated with encorafenib …

Novartis signed two different separate licensing agreements with two development-stage firms, Bluebird (BLUE) and Celyad (CYAD). The signing of the agreements, enabled Novartis to license the two firm’s proprietary technologies, both related to improving Novartis’ genetically engineered immunooncology CAR- T cells. CELYAD The Celyad/Novartis Agreement Celyad announced a non-exclusive license agreement with Novartis for its US patents issued for the production of allogeneic CAR-T cells. …

MIGRAINE Migraine might have a new potent preventive treatment on the market in the near future. The new breakthrough approach towards migraine treatment aims at targeting and inhibiting calcitonin gene–related peptide (CGPR). Four drug developing firms have ongoing clinical trials with drugs targeting CGPR. These are Amgen/Novartis product erenumab (AMG334); Alder Pharmaceuticals’’ product ALD403 and Teva Pharmaceuticals’ product TEV-48125. Each of the monoclonal antibodies has …

CANCER IMMUNOTHERAPY 2 Nonstop Improvements and Nonstop Discoveries In CAR-T Immunotherapy As we said in the article about checkpoint inhibition as cancer immunotherapy, the approaches that aim at enabling the immune system to fight cancer cells were created to stay and improve and become the gold standard for cancer treatment. Chimeric antigen receptor T cell (CAR-T) therapeutics are speeding their way towards approval in 2017. …

CANCER IMMUNOTHERAPY Nonstop Improvements and Nonstop Discoveries Checkpoint inhibitors and CAR-T immunotherapy are created to stay and succeed and change the way cancer has been treated for decades. The reason is that the successful results from some early attempts to enable the immune system to attack and fight cancers through these new immunotherapy approaches were unmatched in the history of cancer treatments. These successes, though, …

Agenus (AGEN) is reorganizing its business and operations. The reasons the firm cited comprise sharpening of its focus on clinical development of its two checkpoint inhibitor antibodies and vaccine program. Among others are: - Closing its Basel site and consolidate key functions to its Cambridge, UK and Lexington, MA facilities, - Phasing out approximately 50 positions across the organization. Robert Stein, M.D., Ph.D., President of …

Everybody knows Bristol-Myers Squibb (BMY), but just a few may know anything about CytomX Therapeutics (CTMX), or about its Probody Program. CytomX is a small, develop-ment-stage firm that created platform known as the Probody Program, which leads to the creation of first in class Probody therapeutics. These therapeutics are meant to overcome safety and efficacy problems encountered by the antibodies that are currently used in …

AMGEN Amgen’s (AMGN) cholesterol lowering drug Repatha is the only drug that has demonstrated protection against heart attack and stroke in high risk patients. Prior to the FOURIER trial, which confirmed the effect of Repatha in lowering cardiovascular events, including heart attack and stroke, other clinical trial data led to the FDA approval of Repatha limited to the following indications: 1) adjunct to diet and …